249 related articles for article (PubMed ID: 12783124)
41. Association of pretreatment thrombocytosis with disease progression and survival in oral squamous cell carcinoma.
Lu CC; Chang KW; Chou FC; Cheng CY; Liu CJ
Oral Oncol; 2007 Mar; 43(3):283-8. PubMed ID: 16920387
[TBL] [Abstract][Full Text] [Related]
42. Thrombocytosis as a prognostic factor in endometrial carcinoma.
Gücer F; Moser F; Tamussino K; Reich O; Haas J; Arikan G; Petru E; Winter R
Gynecol Oncol; 1998 Aug; 70(2):210-4. PubMed ID: 9740692
[TBL] [Abstract][Full Text] [Related]
43. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
[TBL] [Abstract][Full Text] [Related]
44. Prognostic factors affecting disease-free survival in patients at age 35 or younger with invasive breast cancer.
Koca B; Kuru B; Karabicak I; Yürüker SS; Ozen N
Ann Ital Chir; 2014; 85(3):249-53. PubMed ID: 25074433
[TBL] [Abstract][Full Text] [Related]
45. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma.
Göğüş C; Baltaci S; Filiz E; Elhan A; Bedük Y
Urology; 2004 Mar; 63(3):447-50. PubMed ID: 15028435
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
47. The pretreatment thrombocytosis may predict prognosis of patients with colorectal cancer: a systematic review and meta-analysis.
Wang YH; Deng SJ; Yang YD; Yao N; Zhao JM; Min GT; Wang J; Xu TF; Zhao PY; Wang HP; Chen W
Biomark Med; 2017 Feb; 11(2):195-210. PubMed ID: 28097884
[TBL] [Abstract][Full Text] [Related]
48. The prognostic significance of thrombocytosis in ovarian cancer.
Słabuszewska-Jóźwiak A; Dmoch-Gajzlerska E; Kozakiewicz B; Jakiel G
Ann Agric Environ Med; 2015; 22(4):731-5. PubMed ID: 26706987
[TBL] [Abstract][Full Text] [Related]
49. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
[TBL] [Abstract][Full Text] [Related]
50. Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer.
Tanis E; van de Velde CJ; Bartelink H; van de Vijver MJ; Putter H; van der Hage JA
Eur J Cancer; 2012 Aug; 48(12):1751-6. PubMed ID: 22446021
[TBL] [Abstract][Full Text] [Related]
51. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified?
Weissenbacher TM; Zschage M; Janni W; Jeschke U; Dimpfl T; Mayr D; Rack B; Schindlbeck C; Friese K; Dian D
Breast Cancer Res Treat; 2010 Jul; 122(1):27-34. PubMed ID: 20454925
[TBL] [Abstract][Full Text] [Related]
52. Immunoenzymatically determined pepsinogen C concentration in breast tumor cytosols: an independent favorable prognostic factor in node-positive patients.
Scorilas A; Diamandis EP; Levesque MA; Papanastasiou-Diamandi A; Khosravi MJ; Giai M; Ponzone R; Roagna R; Sismondi P; López-Otin C
Clin Cancer Res; 1999 Jul; 5(7):1778-85. PubMed ID: 10430082
[TBL] [Abstract][Full Text] [Related]
53. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
[TBL] [Abstract][Full Text] [Related]
54. Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma.
Claude L; Perol D; Ray-Coquard I; Petit T; Blay JY; Carrie C; Bachelot T
Radiother Oncol; 2005 Sep; 76(3):334-9. PubMed ID: 16024123
[TBL] [Abstract][Full Text] [Related]
55. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
[TBL] [Abstract][Full Text] [Related]
56. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
[TBL] [Abstract][Full Text] [Related]
57. Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.
Cozzi GD; Samuel JM; Fromal JT; Keene S; Crispens MA; Khabele D; Beeghly-Fadiel A
BMC Cancer; 2016 Aug; 16():612. PubMed ID: 27502272
[TBL] [Abstract][Full Text] [Related]
58. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
[TBL] [Abstract][Full Text] [Related]
59. The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer.
Takeuchi H; Abe M; Takumi Y; Hashimoto T; Kobayashi R; Osoegawa A; Miyawaki M; Okamoto T; Sugio K
PLoS One; 2017; 12(12):e0189166. PubMed ID: 29216259
[TBL] [Abstract][Full Text] [Related]
60. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
Harbeck N; Dettmar P; Thomssen C; Berger U; Ulm K; Kates R; Höfler H; Jänicke F; Graeff H; Schmitt M
Br J Cancer; 1999 May; 80(3-4):419-26. PubMed ID: 10408848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
